Anixa Biosciences ANIX Cash Flow Statement (2010-2026)

NASDAQ ANIX
$2.78 +0.07 (+2.58%)
At close: Oct 22, 2026 · 4:00 PM EDT
Reported Financials

Anixa Biosciences Quarterly Cash Flow Statement

Periods 64 quarters
Latest Jul 2026

Anixa Biosciences reported cash from operations of -$1.77M and free cash flow of -$1.77M for the quarter ended Jul 2026, down 17.8% year over year. This cash flow statement covers 64 quarters of results from Jul 2010 through Jul 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jul2010 Oct2010 Jan2011 Apr2011 Jul2011 Oct2011 Jan2012 Apr2012 Jul2012 Oct2012 Jan2013 Apr2013 Jul2013 Oct2013 Jan2014 Apr2014 Jul2014 Oct2014 Jan2015 Apr2015 Jul2015 Oct2015 Jan2016 Apr2016 Jul2016 Oct2016 Jan2017 Apr2017 Jul2017 Oct2017 Jan2018 Apr2018 Jul2018 Oct2018 Jan2019 Apr2019 Jul2019 Oct2019 Jan2020 Apr2020 Jul2020 Oct2020 Jan2021 Apr2021 Jul2021 Oct2021 Jan2022 Apr2022 Jul2022 Oct2022 Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Jan2025 Apr2025 Jul2025 Oct2025 Apr2026 Jul2026
Operating Activities
Net Income
-4.39M-4.07M-3.88M-3.59M-2.78M-3.53M-2.35M-2.31M-2.55M-2.72M-3.29M-3.18M-3.32M-2.91M-3.21M-2.81M-2.28M-2.72M-2.54M-2.63M
Depreciation and DepletionDep. & Depletion
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
Share-based CompensationStock Comp.
3.05M2.70M2.14M1.46M1.33M1.07M0.96M1.16M1.15M1.16M1.11M1.24M1.09M0.98M1.03M0.96M0.83M0.86M0.64M0.64M
Gains from Sales and DivestituresGains Divest
0.00M
Gains from Investment SecuritiesGains Investment
Asset Writedowns and ImpairmentWritedown
Other non-cash itemsOther Non-Cash
0.02M0.02M0.01M0.08M0.02M0.04M0.04M0.04M0.03M0.04M0.11M0.01M0.16M0.01M-0.24M0.18M-0.01M-0.04M0.00M
Change in Working Capital
Change in ReceivablesChange Receivables
0.10M0.11M0.08M-0.06M0.12M-0.17M0.19M-0.24M-0.17M
Change in Account PayablesChange Payables
-0.23M-0.07M0.37M-0.41M0.14M0.04M-0.16M0.09M-0.10M0.11M0.16M-0.15M0.09M0.22M0.08M-0.32M-0.01M-0.11M0.03M
Change in Accured ExpensesChange Accured Exp.
0.01M0.10M0.15M-0.18M0.14M0.53M-0.65M0.22M0.42M0.06M-0.53M0.17M0.27M0.27M-0.58M0.20M0.19M0.01M0.21M
Change in Other Operating AssetsOther Assets Change
0.06M-0.16M0.19M-0.13M0.34M-0.19M-0.21M-0.08M0.35M0.71M-0.21M-0.27M0.76M-0.25M0.17M-0.26M0.25M-0.71M0.10M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.02M-0.01M-0.01M-0.01M-0.01M-0.01M-0.01M-0.01M-0.01M-0.01M-0.01M-0.01M-0.01M-0.01M0.00M-0.01M-0.01M-0.01M-0.01M
Other Working Capital ChangesOther WC Changes
-0.08M0.15M-0.20M0.12M-0.35M0.18M0.20M0.07M-0.36M-0.72M0.20M0.26M-0.77M0.25M-0.17M0.25M-0.26M0.70M-0.11M
Cash from OperationsCash from Ops.
-1.48M-1.05M-1.20M-2.31M-1.40M-1.59M-1.99M-0.81M-1.45M-1.97M-2.31M-1.46M-2.64M-0.93M-2.90M-1.50M-1.51M-1.26M-1.77M
Investing Activities
Capital ExpendituresCapex
Sales of Property, Plant and EquipmentPP&E (Sale)
Change in Property, Plant and EquipmentChange in PP&E
Purchase of InvestmentsInvestments Purchased
6.10M3.50M0.75M6.91M11.33M7.84M9.57M10.10M16.91M20.02M14.72M12.57M16.46M13.00M11.93M11.77M7.66M9.78M
Sale and Maturity of InvestmentsInvestments Sold
1.00M8.90M5.35M1.00M4.00M1.41M7.25M6.13M9.12M16.32M20.15M15.27M15.29M17.33M15.70M14.27M10.94M8.31M9.53M
Other Investing ActivitiesOther investing
Cash from Investing ActivitiesCash from Investing
1.00M2.81M1.85M0.25M-2.91M-9.92M-0.59M-3.44M-0.98M-0.59M0.13M0.56M2.72M0.87M2.70M2.34M-0.83M0.65M-0.25M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Non-Current Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
-2.41M0.83M-0.38M0.00M0.08M0.00M0.28M2.26M0.90M0.15M0.11M-0.02M0.02M1.93M0.46M1.94M
Net Shares Issued and RepurchasedNet Shares Issued
-2.41M0.83M-0.38M0.00M0.08M0.00M0.28M2.26M0.90M0.15M0.11M-0.02M0.02M1.93M0.46M1.94M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
-2.41M0.83M-0.38M0.00M0.08M0.00M0.28M2.26M0.90M0.15M0.11M-0.02M0.02M1.93M0.46M1.94M
Other financing activitiesOther financing
Cash from Financing ActivitiesCash from Financing
0.14M0.83M-0.38M0.00M0.08M0.00M0.28M2.26M0.90M0.15M0.11M-0.02M0.02M1.93M0.35M1.94M
Additional items
Change in Cash
-0.48M1.91M0.65M-2.05M-3.48M-11.89M-2.57M-4.17M-2.42M-2.28M0.08M0.00M0.23M0.05M-0.22M0.86M-0.42M-0.25M-0.08M
Ending Cash Balance
27.22M29.13M29.78M27.73M24.25M12.36M9.79M5.62M3.20M0.92M1.00M1.00M1.23M1.27M1.05M1.91M1.50M1.24M1.48M1.40M
Free Cash FlowFCF
-1.48M-1.05M-1.20M-2.31M-1.40M-1.59M-1.99M-0.81M-1.45M-1.97M-2.31M-1.46M-2.64M-0.93M-2.90M-1.50M-1.51M-1.26M-1.77M
Net Cash FlowNCF
-0.48M1.91M0.65M-2.06M-3.48M-11.89M-2.57M-4.17M-2.42M-2.28M0.08M0.00M0.23M0.05M-0.22M0.86M-0.42M-0.25M-0.08M
Interest Paid
277.00325.00

Anixa Biosciences Cash Flow Statement API

Pull Anixa Biosciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ANIX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY